lisocabtagene maraleucel,Axicabtagene Ciloleucel,Cyclophosphamide,Fludarabine,Luspatercept
bms,Gilead
['dlbcl', 'lymsm', 'cml']
in conclusion, car-t is curative intent (~30-40%) and is superior to asct for pfs and os for primary refractory and relapsed &lt;12 mos dlbcl. trials coming about bringing car into the first line. #lymsm #17icml #tcellrx 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈